In 1998 was created LBBW VC, which is appeared as VC. The fund was located in Europe if to be more exact in Germany. The main office of represented VC is situated in the Stuttgart.
Besides them, we counted 3 critical employees of this fund in our database.
The increased amount of exits for fund were in 2015. The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is generally included in less than 2 deals every year. Deals in the range of 5 - 10 millions dollars are the general things for fund. Opposing the other organizations, this LBBW VC works on 10 percentage points less the average amount of lead investments. Speaking about the real fund results, this VC is 4 percentage points more often commits exit comparing to other organizations.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - Germany. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Biotechnology. The fund has exact preference in some founders of portfolio startups. When startup sums 1 or 5+ of the founder, the probability for it to get the investment is little. Among the most popular portfolio startups of the fund, we may highlight tadou00b0, PressMatrix, Biametrics GmbH.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the LBBW VC, startups are often financed by High-Tech Gru00fcnderfonds, KfW, HBM Healthcare Investments AG. The meaningful sponsors for the fund in investment in the same round are High-Tech Gru00fcnderfonds, Bayern Kapital GmbH, Logan Capital AG. In the next rounds fund is usually obtained by Bayern Kapital GmbH, bmp Ventures, KfW.
Funds with similar focus
|Chuchuang Investment||China, Shanghai|
|Collinstar Capital||Australia, Melbourne, Victoria|
|E Squared Capital Management||New York, New York, United States|
|France Telecom (now Orange S.A.)||France, Ile-de-France, Issy-les-moulineaux|
|Fresenius Medical Care||Bad Homburg, Germany, Hessen|
|Galaxy Ventures||Belmont, California, United States|
|GMO Pepabo||Japan, Tokyo|
|Guangzhou Zexian Touzi Hehuo Qiye||-|
|Innoven Partners||France, Ile-de-France, Paris|
|Leon Capital Group LLC||Dallas, Texas, United States|
|Muhua Jinxin Investment Management||-|
|Opus||California, Palo Alto, United States|
|Ruifu Investment||China, Shanghai|
|Seeqnce||Beirut, Beyrouth, Lebanon|
|Tianjin Huacheng Oulun Investment Management||China, Guangdong, Tianjin|
|Verus International||New York, New York, United States|
|VisVires Capital||France, Ile-de-France, Paris|
|$12M||01 Jun 2022||Bonn, North Rhine-Westphalia, Germany|
|$3M||17 Feb 2022||Freiburg, Baden-Wurttemberg, Germany|
|$10M||26 Oct 2021||Heidelberg, Baden-Württemberg, Germany|
|$12M||22 Apr 2021||Berlin, Berlin, Germany|
|$4M||02 Mar 2021||Mainz, Rheinland-Pfalz, Germany|
|$2M||24 Jun 2020||Germany, North Rhine-Westphalia|
|$17M||06 Aug 2019||Zurich, Zurich, Switzerland|
|$2M||20 Dec 2018||Bavaria|
|$11M||14 May 2018||Baden-Württemberg|
– ActiTrexx is a new biotech spin-off from the University Medical Center Mainz, Germany.
– The company closed its €3.5m Series A funding.
– The round was led by LBBW Venture Capital GmbH with participation from MediVentures GmbH, High-Tech Gründerfonds (HTGF) and Investitions- und Strukturbank Rheinland-Pfalz (ISB).
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.